Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Manufactures, marketes and imports, exports pharmaceutical drugs

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company

Shenzhen Maigisell Biotechnology Co., Ltd., established on 2017-11-28, Business scope includes general business items:Research and development of stem cell and tumor immune cell therapy technology,Application and promotion;Construction and investment of tissue cell bank;cell storage;Sales of electronic equipment;Biotechnology Services and Consulting;Research and development of bioengineering technology,technology transfer,technical consulting;biological reagent,R&D and sales of consumables and instruments(Does not contain drugs);medicine,Biological product,biomaterials,Biomedical,biohealth,Technology research and development of biological gene technology and products,technology transfer,technical consulting,Technical Services;Health management and health consulting services(Does not contain medical behavior);Investment in medical institutions,manage,Enterprise management information consulting service;Sales:cosmetic,skin care products,Health Supplies,Biological product,Class I medical device(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).Research and development of bioengineering technology,Technology transfer,Technical Services;Biotechnology Consulting,Technical exchange service;research and development,Sales:biological reagent(Does not contain drugs and medical devices);medicine,Research and Development of Biomaterials,technical consulting,technology transfer,Technical Services;Sales:Health Supplies,medical instruments(Class I medical device,Class II medical device);stem cell,Tumor immune cell technology research and development,technical consulting,technology transfer;Cell bank construction and investment;collection of stem cells,save,preparation service;Collection of immune cells,save,preparation service;Stem Cell Drug Development;Research and development of biomedical technology;Health Consulting Services;Medical institution project investment;Business Management Consulting;Sales of electronic equipment;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments),The licensing program is:research and development,Production:cosmetic,skin care products,Health Supplies,Biological product,Class I medical device;Sales of health products;research and development,production and sales:Class II medical device.research and development,Production:Health Supplies,medical instruments(Class I medical device,Class II medical device);

ROKIT Healthcare provides hardware, software, and application support. Their custom fabrication technologies deliver solutions to the design, creation, and applications of three-dimensional systems. They provide suffering patients and humans with a hyper-personalized medical organ regeneration solution. They apply artificial intelligence and 3d bioprinting technology to regenerate the skin and cartilage organs through surgery for patients.

Hengyang Maochen Agricultural Development Co., Ltd., established on 2014-06-05, Business scope includes seedling planting;Planting and sales of Chinese herbal medicines;poultry,livestock,bullfrog,frog,Freshwater fish farming and sales.(The above business scope does not include pre-licensed items,Those involving post-approval must be approved before they can operate)

Manufactures pharmaceuticals and diagnostic substances

Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.

TEDA International Cardiovascular Hospital (Chinese: 泰达国际心血管病医院) is a specialist cardiovascular hospital in the Binhai New Area of Tianjin, China.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Beijing Hanmei Biotechnology Co., Ltd., established on 2020-03-16, Business scope includes technology development,Technical Services,technical consulting,technology transfer,Technology Promotion;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;product design;Computer System Services;software development;software consulting.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Asahi Kasei Pharma Corp., a subsidiary of Asahi Kasei Corp., is a company headquartered in Tokyo, Japan, that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

Chongqing Aixi Baicao focuses on the health of children aged 0-12, and is the choice of thousands of mothers! Chongqing Aixi Baicao Biotechnology Co., Ltd., originating from the mysterious Yao nationality, is a biotechnology enterprise focusing on children's medicine bath, children's massage, children's health management, product research and development, technology innovation and other fields. We take medicine bath as the carrier, integrate children's massage, medicine bag moxibustion and washing, and multi-ethnic traditional therapy, and comprehensively develop, innovate, and practice new medicine bath categories. The company has a number of "invention patents", "national intangible cultural heritage" products, and a number of authoritative Chinese medicine experts and a professional service team. Scope of recuperation: newborn jaundice, fetal toxin, eczema, urticaria, prickly heat, children's acute rash, children's sub-health, cold, cough, rhinorrhea, runny nose, tonsillitis, asthma, food accumulation, halitosis, anorexia, constipation, diarrhea, night terrors, growth retardation, five lateness and five softness and other spleen and stomach, kidney diseases have good health care, rehabilitation and recuperation effects. The company expands the market with business models such as whole store franchise, project franchise and regional agency, and is determined to promote the enterprise concept and "green therapy" of Aixi Baicao to the whole country. Aixi Baicao makes children healthier! At present, the company has 200 franchise stores all over the country, covering more than 20 provinces and cities, and has successively settled in Sichuan, Yunnan, Inner Mongolia and other hospitals. Aixi Baicao aims to "excavate the essence of famous families, inherit their treasures, and advocate green therapy to make children healthier". Be the inheritor of famous national treasures and the disseminator of green therapy; With the mission of "making children healthier", we will become a famous Chinese brand.